9 trends tracked about this subject — the full history, oldest to newest below.
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
Takeda has released Phase 3 study data for oveporexton, a new drug designed to treat the excessive daytime sleepiness associated with narcolepsy.
The pharmaceutical company Takeda has released Phase 3 data for oveporexton, a transformative drug targeting narcolepsy type 1 symptoms.
Silence Therapeutics advances its gene-silencing drug divesiran toward Phase III following mid-stage trial success in polycythemia vera.
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.
Takeda secures FDA approval for Orzeyful, launching a new class of treatments targeting the underlying cause of narcolepsy type 1.
India has approved its first dengue vaccine as South Asian cases surge, introducing Takeda's TAK-003 to an at-risk population.
India has approved Takeda's Qdenga, marking the first time a dengue vaccine has been cleared for use within the country.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.